.

Make Better Decisions

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Baxter
Mallinckrodt
Fuji
Farmers Insurance
Novartis
Federal Trade Commission
Deloitte
Covington
McKesson
Harvard Business School

Generated: November 22, 2017

DrugPatentWatch Database Preview

TORISEL Drug Profile

« Back to Dashboard

What is the patent landscape for Torisel, and what generic Torisel alternatives are available?

Torisel is a drug marketed by Pf Prism Cv and is included in one NDA. There are seven patents protecting this drug and one Paragraph IV challenge.

This drug has forty-eight patent family members in twenty-eight countries and ten supplementary protection certificates in eight countries.

The generic ingredient in TORISEL is temsirolimus. There are five drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the temsirolimus profile page.
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pf Prism Cv
TORISEL
temsirolimus
SOLUTION;INTRAVENOUS022088-001May 30, 2007RXYesYes► Subscribe► SubscribeY► Subscribe
Pf Prism Cv
TORISEL
temsirolimus
SOLUTION;INTRAVENOUS022088-001May 30, 2007RXYesYes► Subscribe► Subscribe ► Subscribe
Pf Prism Cv
TORISEL
temsirolimus
SOLUTION;INTRAVENOUS022088-001May 30, 2007RXYesYes► Subscribe► SubscribeY► Subscribe
Pf Prism Cv
TORISEL
temsirolimus
SOLUTION;INTRAVENOUS022088-001May 30, 2007RXYesYes► Subscribe► SubscribeY► Subscribe
Pf Prism Cv
TORISEL
temsirolimus
SOLUTION;INTRAVENOUS022088-001May 30, 2007RXYesYes► Subscribe► SubscribeY► Subscribe
Pf Prism Cv
TORISEL
temsirolimus
SOLUTION;INTRAVENOUS022088-001May 30, 2007RXYesYes► Subscribe► SubscribeY► Subscribe
Pf Prism Cv
TORISEL
temsirolimus
SOLUTION;INTRAVENOUS022088-001May 30, 2007RXYesYes► Subscribe► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV (Patent) Challenges for TORISEL

Drugname Dosage Strength RLD Submissiondate
temsirolimusInjection25 mg/mL, 1.8 mL vialTorisel5/25/2011

International Patent Family for Tradename: TORISEL

Country Document Number Estimated Expiration
Germany69535363► Subscribe
Netherlands300348► Subscribe
Mexico9604694► Subscribe
Slovakia281787► Subscribe
Germany122008000023► Subscribe
Portugal763039► Subscribe
Denmark0763039► Subscribe
European Patent Office1266899► Subscribe
Spain2375730► Subscribe
Portugal1266899► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: TORISEL

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
00348Netherlands► SubscribePRODUCT NAME: TEMSIROLIMUS, DESGEWENST IN DE VORM VAN EEN; REGISTRATION NO/DATE: EU/1/07/424/001 20071119
0763039/01Switzerland► SubscribePRODUCT NAME: TEMSIROLIMUS; REGISTRATION NUMBER/DATE: SWISSMEDIC 58100 12.12.2008
C017/2008Ireland► SubscribeSPC017/2008: 20090911, EXPIRES: 20200413
C/GB08/025United Kingdom► SubscribePRODUCT NAME: TEMSIROLIMUS AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTERED: UK EU/1/07/424/001 20071119
438Luxembourg► Subscribe91438, EXPIRES: 20200414
2008009Lithuania► SubscribePRODUCT NAME: TEMSIROLIMUSUM; REG. NO/DATE: EU/1/07/424/001 20071119
0348Netherlands► Subscribe300348, 20150414, EXPIRES: 20200413
2008 00028Denmark► Subscribe
C0018France► SubscribePRODUCT NAME: TEMSIROLIMUS; REGISTRATION NO/DATE: EU/1/07/424/001 20071119
2008009,C0763039Lithuania► SubscribePRODUCT NAME: TEMSIROLIMUSUM; REGISTRATION NO/DATE: EU/1/07/424/001 20071119
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Citi
US Army
Julphar
Baxter
Queensland Health
Novartis
QuintilesIMS
Merck
Johnson and Johnson
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot